Farnesyl protein transferase inhibition interferes with activation of MAP kinase family members in human peripheral blood monocytes

Molecular Medicine

Volumn 8, Issue 12, 2002, Pages 857-862

  Vervenne, Walter L ^a   Bos, Carina L ^a   Rens, Linda S ^a   Peppelenbosch, Maikel P ^a   Richel, Dick J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; FTI 744832; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P42; PROTEIN P44;

ARTICLE; BLOOD; CELL FUNCTION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; MONOCYTE; PRIORITY JOURNAL; PROTEIN FAMILY; VOLUNTEER; WESTERN BLOTTING;

EID: 0037000161     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402091     Document Type: Article

References (22)

1. Gibbs JB, Oliff A. (1997) The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol. 37: 143-166.
2. Cox AD, Der CJ. (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta 1333: F51-F71.
3. James GL, Goldstein JL, Brown MS, et al. (1993) Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260: 1937-1942.
4. Manne V, Yan N, Carboni JM, et al. (1995) Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene 10: 1763-1779.
5. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. (1995) Inhibition of human tumor xenograft growth by treatment with the farnesyl protein transferase inhibitor B956 Cancer Res. 55: 5310-5314.
6. Prendergast GC, Davide JP, deSolms SJ, et al. (1994) Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton NE. Mol. Cell. Biol. 14: 4193-4202.
7. Sepp-Lorenzino L, Ma Z, Rands E, et al. (1995) A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55: 5302-5309.
8. Sun J, Qian Y, Hamilton AD, Sebti SM. (1995) Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. 55: 4243-4247.
9. Adamson P, Marshall CJ, Hall A, Tilbrook PA. (1992) Posttranslational modifications of p21rho proteins. J. Biol. Chem. 267: 20033-20038.
10. Du W, Lebowitz PF, Prendergast GC. (1999) Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol. 19: 1831-1840.
11. Sepp-Lorenzino L, Ma Z, Rands E, et al. (1995) A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55: 5302-5309.
12. Kohl NE, Omer CA, Conner MW, et al. (1995) Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1: 792-797.
13. Norgaard P, Law B, Joseph H, et al. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res. 5: 35-42.
14. Law BK, Norgaard P, Gnudi L, et al. (1999) Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway. J. Biol. Chem. 274: 4743-4748.
15. Mahgoub N, Taylor BR, Gratiot M, et al. (1999) In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood 94: 2469-2476.
16. van den Blink B, Juffermans NP, ten Hove T, et al. (2001) p38 mitogen-activated protein kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo. J. Immunol. 166: 582-587.
17. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5: 810-816.
18. Branger J, van Den Blink B, Weijer S, et al. (2002) Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. 168: 4070-4077.
19. Hommes D, van den Blink B, Plasse T, et al. (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122: 7-14.
20. Mizukami Y, Ura H, Obara T, et al. (2001) Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 288: 198-204.
21. Kolch W, Heidecker G, Kochs G, et al. (1993) Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364: 249-252.
22. Lebowitz PF, Davide JP, Prendergast GC. (1995) Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell. Biol. 15: 6613-6622.